Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. Histologically confirmed diagnosis of squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin.~3. Measurable disease according to RECIST 1.1.~4. Defined time to tumour progression on the standard/experimental treatment preceding the trial treatment.~5. Locally advanced or metastatic disease not amenable to standard treatment, i.e. progress on standard therapy or observed/expected intolerance to standard therapy.~6. - (removed via Amendment 1)~7. Pharmacological treatment attempt considered reasonable.~8. Females of childbearing potential should use adequate contraception throughout the study;~   1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal)~  2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable)~  3. Intrauterine device (IUD)~  4. Intrauterine hormone-releasing system (IUS)~  5. Bilateral tubal occlusion~  6. Vasectomized partner~  7. Sexual abstinence~9. Signed informed consent.~Exclusion Criteria:~1. Anti-tumour therapy within 3 weeks prior to study drug administration day~2. Ongoing infection or other major recent or ongoing disease that, according to the investigator, poses an unacceptable risk to the patient.~3. WHO performance status ≥ 2.~4. Child-Pugh B or C liver function status if hepatocellular carcinoma.~5. Inadequate laboratory parameters reflecting major organ function i.e.:~   1. neutrophils ≤ 1,3 x 109/l~  2. platelets ≤ 100 x 109/l~  3. bilirubin \> 1.5 x upper limit of normal (ULN)~  4. Alanine aminotransferase (ALAT) \> 5 x ULN~  5. Glomerular filtration rate (GFR) \<50 ml/min (calculated from P-creatinine)~  6. Prothrombin complex/INR outside normal range~6. Current active participation in any other interventional clinical study.~7. Contraindications to the investigational product, e.g. known or suspected hypersensitivity or inability to oral drug administration.~8. Pregnancy or lactation.~9. Lack of suitability for participation in the study, e g expected difficulties to follow the protocol procedures, as judged by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm study (Type: EXPERIMENTAL): ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).